Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: A randomized trial

European Journal of Endocrinology

Volumn 174, Issue 2, 2016, Pages 147-155

  Tian, Mingyuan ^a   Liang, Zerong ^a   Liu, Rui ^a   Li, Ke ^a   Tan, Xinrong ^a,b   Luo, Yong ^c   Yang, Mengliu ^a   Gu, Harvest F ^d   Liu, Hua ^e   Li, Ling ^a   Yang, Gangyi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b 9th People's Hospital of Chongqing   (China)

^c CHONGQING THREE GORGES UNIVERSITY   (China)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; GLYCOPROTEIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SEMINAL PLASMA PROTEIN; TNF PROTEIN, HUMAN; ZN-ALPHA-2-GLYCOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; OUTCOME ASSESSMENT; PHYSIOLOGY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SEMINAL PLASMA PROTEINS; SITAGLIPTIN PHOSPHATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956604126     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0637     Document Type: Article

References (31)

1. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556. (doi:10.1210/jc.2004-0395)
2. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes/Metabolism Research and Reviews 2002 18 (Suppl 2) S5-S9. (doi:10.1002/dmrr.254)
3. Fantuzzi G. Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 2005 115 911-919 quiz 920. (doi:10. 1016/j.jaci.2005.02.023)
4. Burgi W & Schmid K. Preparation and properties of Zn-A 2-glycoprotein of normal human plasma. Journal of Biological Chemistry 1961 236 1066-1074.
5. Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H & Eimoto T. Immunohistochemical localization of Zn-A 2-glycoprotein in normal human tissues. Journal of Histochemistry and Cytochemistry 1991 39 1221-1226. (doi:10.1177/39.9.1918940)
6. Bao Y, Bing C, Hunter L, Jenkins JR,Wabitsch M & Trayhurn P. Zinc-A2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Letter 2005 579 41-47. (doi:10.1016/j.febslet.2004.11.042)
7. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ & Trayhurn P. Zinc-A2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. PNAS 2004 101 2500-2505. (doi:10.1073/pnas.0308647100)
8. Yeung DC, Lam KS, Wang Y, Tso AW & Xu A. Serum zinc-A2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. Journal of Clinical Endocrinology and Metabolism 2009 94 2531-2536. (doi:10.1210/jc.2009-0058)
9. Eckardt K, Schober A, Platzbecker B, Mracek T, Bing C, Trayhurn P & Eckel J. The adipokine zinc-A2-glycoprotein activates AMP kinase in human primary skeletal muscle cells. Archives of Physiology and Biochemistry 2011 117 88-93. (doi:10.3109/13813455.2011.560950)
10. Yang M, Liu R, Li S, Luo Y, Zhang Y, Zhang L, Liu D, Wang Y, Xiong Z, Boden G et al. Zinc-A2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 2013 36 1074-1082. (doi:10.2337/dc12-0940)
11. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998 15 539-553. (doi:10.1002/(SICI)1096-9136(199807)15:7!539::AID-DIA668O3.0.CO;2-S)
12. Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H & Yang G. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. Journal of Clinical Endocrinology and Metabolism 2013 98 290-298. (doi:10.1210/jc.2012-2466)
13. Jia Y, Yuan L, Hu W, Luo Y, Suo L, Yang M, Chen S, Wang Y, Liu H, Yang G et al. Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans. Journal of Internal Medicine 2014 275 522-533. (doi:10.1111/joim.12170)
14. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A & Corcoy R. Assessment of insulin sensitivity and b-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000 43 1507-1511. (doi:10.1007/s001250051561)
15. Forst T & Bramlage P. Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 2014 15 1299-1313. (doi:10.1517/14656566.2014.920009)
16. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I & Barnett AH. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-Analysis. Diabetes, Obesity & Metabolism 2014 16 433-442. (doi:10.1111/dom.12239)
17. Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M & Woerle HJ. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: A comprehensive analysis of data from 1331 individuals agedR65 years. Diabetes, Obesity & Metabolism 2014 16 1078-1086. (doi:10.1111/dom.12321)
18. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity & Metabolism 2014 16 1016-1027. (doi:10.1111/dom.12348)
19. Esposito K, Chiodini P, Maiorino MI, Capuano A, Cozzolino D, Petrizzo M, Bellastella G & Giugliano D. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: A systematic review and meta-Analysis of 98 trials with 24 163 patients. BMJ Open 2015 5 e005892. (doi:10.1136/bmjopen-2014-005892)
20. Yang HK, Kang B, Lee SH, Kim HS, Yoon KH, Cha BY & Cho JH. Effects of 6-month sitagliptin treatment on insulin and glucagon responses in Korean patients with type 2 diabetes mellitus. Diabetes & Metabolism Journal 2015 39 335-341. (doi:10.4093/dmj.2015.39.4.335)
21. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH & Pederson RA. Long-Term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study. Diabetes 2002 51 2677-2683. (doi:10.2337/diabetes.51.9.2677)
22. Ahren B, Pacini G, Foley JE & Schweizer A. Improvedmeal-related b-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-Treated patients with type 2 diabetes over 1 year. Diabetes Care 2005 28 1936-1940. (doi:10.2337/diacare.28.8.1936)
23. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ & Burrell MA. The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology. Endocrinology and Metabolism 2001 280 E827-E847.
24. Kern M, Kloting N, Niessen HG, Thomas L, Stiller D, Mark M, Klein T & Bluher MP. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012 7 e38744. (doi:10.1371/journal.pone.003874)
25. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Hormone and Metabolic Research 2010 42 663-669. (doi:10.1055/s-0030-1255036)
26. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY & Chuang LM. Synthetic peroxisome proliferator-Activated receptor-g agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002 25 376-380. (doi:10.2337/diacare.25.2.376)
27. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M & Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002 51 2968-2974. (doi:10.2337/diabetes.51.10.2968)
28. Boden G, Cheung P, Mozzoli M & Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003 52 753-759. (doi:10.1016/S0026-0495 (03)00055-6)
29. Rizzo MR, Barbieri M, Marfella R & Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012 35 2076-2082. (doi:10.2337/dc12-0199)
30. Tremblay AJ, Lamarche B, Deacon CF,Weisnagel SJ & Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014 63 1141-1148. (doi:10.1016/j.metabol.2014.06.004)
31. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K & Shimatsu A. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts antiinflammatory effects in type 2 diabetic patients. Metabolism 2013 62 347-351. (doi:10.1016/j.metabol.2012.09.004)